Evaluation of combinational effect of Aprepitant on nausea and vomiting induced by chemotherapy (moderate risk) in patients with Gastric Cancer or Colorectal Cancer
Not Applicable
- Conditions
- Inoperable advanced/recurrence Gastric Cancer or Colorectal Cancer
- Registration Number
- JPRN-UMIN000008041
- Lead Sponsor
- Osaka Medical College Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patient who has severe liver failure or renal failure (2) Patient who has vomited or provoked nausea in the 24 hours prior to start of chemotherapy (3) Patient who has a factor that induces nausea or vomitting except chemotherapy (brain tumor, obstruction of gastrointestinal tract, active peptic ulcer, brain metastasis et al) (4) Patient who is considered inappropriate as a target patient by a physician-in-charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method